Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 paclitaxel plus tislelizumab study in angiosarcoma
MOH_2025-12-28_015569Phase 2Not yet recruiting
- Sponsor
- ד"ר דניאלה כץ
- Start
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and tislelizumab in angiosarcoma, sponsored by ד"ר דניאלה כץ. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
paclitaxeltislelizumab
03
Conditions
angiosarcoma
Beyond the preview
Go deeper on MOH_2025-12-28_015569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-12-28_015569.